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Abstract
1. Sinomenine and Irgapyrin, the two antirheumatics known to be capable of releasing his-
tamine, caused a marked gastric secretion in the unanesthetized dog. 2. The facial edema and
itching associated with histamine release by sinomenine was almost completely eliminated by
NeoAntergan, but the gastric secretion was not suppressed, or rather increased - an observation
also reported by Paton and Schachter with Compound 48/80. This indicates that the histamine re-
lease cannot be markedly prevented by antihistamine agents in this animal. 3. The gastric secretion
induced by Irgapyrin was not suppressed by Neo-Antergan but Irgapyrin originally never caused
other symptoms associated with histamine release. This is probably due to the antihistamine action
inherent in this compound itself. 4. No such histamine-releasing activity, as determined by gastric
secretion, could be observed in aminopyrine or butazolidine sodium, the components of Irgapyrin.
5. Sinomenine, differing from Irgapyrin and Compound 48/80, was ineffective by intramuscular
injection.
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Paton and Schachter (1951) observed that a histamine-
releasing substance, Compound 48/80, caused secretion of a
large amount of gastric juice in the unaIlesthetized dog. They
showed that .symptoms associated with n~stamine release, such
\
as facial swelling and itching, were almost completely elimi-
nated by mepyramine, but the amount of histamine liberated,
as determined by the amount of gastric secretion, was not re-
duced.
In recent times, the histamine-releasing action of sinomenine
(Mayeda, 1953, 1954) and Irgapyrin (Yamasaki et al., 1955;
Kume) was found in this laboratory, but not that of amino-
pyrine and butazolidine sodium (Kume). However, no studies
have yet been made on the effect of these drugs on the gastric
secretion. More recently, Tasaka (1956) observed that the rate
of histamine release from the minced skin of a dog induced by
sinomenine and anaphylatoxin was markedly reduced by Bena-
dryl and Neo-Antergan (mepyramine) in a dilute concentration.
This latter finding does not agree with that of Paton and
Schachter.
The present series of ex:periments were undertaken in order
to observe the action of these antirheumatics on gastric secretion
and the effect of Neo-Antergan on such action, examined in
unanesthetized dogs according to the technique of Paton and
Schachter.
Methods
Female dogs of 9·-11 kg. weight were equipped with a
1) Preliminary abstract in Folia pharmacol. japon. 52, 81 § (1956)
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gastric cannula made of nickel-plated brass. Cannula was stop-
pered when not in use. These dogs had been trained to stand
quietly for a certain length of time supported by a few bands in
a frame for the collection of gastric juice. Under such a condi-
tion, secretion of gastric juice was very small, being less than
5 cc. per hour at the most, and the juice was very low in acidity
or even alkaline. There were no indications of bile regurgitation
during all the experiments. The gastric juice, collected every
15 minutes and filtered, was titrated for total hydrochloric acid
with phenolphthalein as the indicator.
The thickness of the cheeks of these dogs was measured
with a micrometer, lightly loaded with a suitable spring, at
2 cm. above the corner of the mouth. The measurement was
shown by the mean value of the readings, but the difference
never exceeded 0.2 mm.
Histamine dihydrochloride, sinomenine hydrochloride2, and
Irgapyrin, and in some experiments, aminopyrine, butazolidine
sodium, and Compound 48/80:\ were administered by subcuta-
neous injection. In case Neo-Antergan was used at the same
time, it was injected subcutaneously 15 minutes prior to the
administration of other drugs.
Results
Subcutaneous injection of 15 mg. of sinomenine hydrochlo-
ride caused severe signs of itching, facial swelling, and marked
secretion of gastric juice, as reported by Paton and Schachter
with Compound 48/80. Pruritus was learned from the move-
ment of the dog, such as licking of the upper lip and the nose
and rubbing the face against the frame, and this was the first
symptom that appeared. Facial swelling was marked around
the mouth, eyelids, and ear-flaps, and accompanied with ery-
thema in these area and areola of the nipples. Secretion of
gastric juice began 5--10 minutes after the injection, showed
the maximum in the second 15-minute period, and continued for
one and half hours or more (Fig. 1). This gastric response was
2) Supplied through the courtesy of the Shionogi Research Lahoratories,
Imafuku 192, Amagasaki.
3) Kindly supplied by Dr. Edwin J. de Beer, the Welcome Research Labora-
tories, Tuckahoe 7, New York.
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approximately comparable to that to 10 mg. of Compound 48/80
used by Paton and Schachier.
Table 1. Gastric secretion produced by sinomenine
with and without Neo-Antergan
In all experiments sinomenine hydrochloride 15 mg. was given subcu-
taneously. Italic figures refer to experiments in which Neo-Antergan
was injected subcutaneously 15 minutes before sinomenine. Neo-Anter-
gan dosis: 2 mg./kg. in no. 2 and 3; 5 mg/.kg. in no. 1 and 4.
Ratio of secretion
Dog cc. 0.1 N-HCl seC'reted on days: after sinomenine +
(Serial no.) Neo-Antergan to1 6 11 16 secretion after
sinomenine alone
1 82.8 41.8 44.8 87.8 1.97
2 53.3 56.7 67.4 27.0 1.55
3 76.3 39.4 37.9 68.5 1.87
4 26.3 25.3 36.8 12.1 1.62
Total 238.7 163.2 186.9 195.4 Av. 1. 75
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Fig. 1. Gastric secretion in cc. 0.1 N-HCl per 15-minute sample and per cent
increase in cheek thickness, produced hy sinomenine hydrochloride 15 mg. sub-
cutaneously at zero time (left) and by the same injection of sinomenine with
Neo-Antergan 5 mg./kg. subcutaneously 15 minutes previomly (right). Each is
thl' average of two cross-over tests. Dog. no. 1.
After subcutaneous injection of 2 or 5 mg./kg\ of Neo-
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Antergan sinomenine caused no apparent signs of pruritus,
swelling, or erythema, although the gastric secretion was not
suppressed but rather increased (Fig. 1 and Table 1). In the
dose used, Neo-Antergan itself did not affect gastric secretion.
The gastric secretion induced by sinomenine developed a
temporary state of complete refractoriness when the injection
was repeated at a short interval but even under such conditions,
the response to histamine did not decrease so markedly. When
the interval of injection was prolonged to over 2--3 days, the
responsiveness to sinomenine returned, though insufficiently.
This phenomenon may be explained by the fact that the depleted
tissue histamine takes a long time to recover (Feldberg and
Talesnik, 1953).
Gastric secretion comparable to that induced by the fore-
going dose of sinomenine was caused by 0.5 mg. of histamine.
Table 2. Gastric secretion produced by histamine with
and without Neo-Antergan
In all experiments histamine dihydrochloride 0.5 mg. subcutaneously.
Italic figures refer to experiments in which Neo-Antergan was given
subcutaneously 15 minutes before histamine. Neo-Antergan dosis:
2 mg.jkg. in no. 6 and 7; 5 mg.jkg. in no. 5 aud 8.
Ratio of secretion
Dog cc. 0.1 N-HCI secreted on days: after histamine -:-
(Serial no.) Neo-Antergan to1 4 7 10 secretion after
histamine alone
5 73.8 66.8 86.0 50.3 1.23
6 56.1 39.1 48.1 44.3 1.15
7 42.4 47.5 41.6 31.3 1.21
8 40.9 39.6 36.4 40.1 1.07
Total 211.1 193.0 212.1 162.9 Av. 1.17
However, facial edema was externally indistinct and precise
measurement showed less than 10 % increase in the thickness of
the cheek. Signs of itching were entirely absent. Neo-Antergan
was also able to cancel even the slight swelling of the cheek
elicited by histamine but increased the gastric secretion by his-
tamine in all the cases, though in a very slight degree (Table 2).
Reduction of the response of gastric secretion by repeated injec-
tions of histamine was slight and the responsiveness was restored
4
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Table 3. Gastric secretion produced by Irgapyrin
with and without Neo-Antergan
Irgapyrin 100 mg,/kg. subcutaneously. Italic figures refer to experi-
ments in which Neo-Antergan was injected subcutaneously 15 minutes
before Irgapyrin. Neo-Antergan dosis:' 2 mg./kg. in no.10; 5 mg./kg.
in no. 9.
0.1 N-HCl Recreted on dayR:Dog
(Serial no.)
cc.
1 5 9 13
Ratio of secretion
after Irgapyrin +
Neo-Antergan to
secretion after
Irgapyrin alone
9
10
31. 3
47.5
29.7
47.7
32.7
49.8
29.3
46.5
1.03
0.96
Total 78.8 77.4 82.5 75 8 Av. 1.00
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Fig. 2. Gastric secretory responses in total cc. 0.] N-HCl to intra-
muscularly injected sinomenine, Irgapyrin and Compound 48/80.
Inability of intramuscularly injected sinomenine is contrasted with
a distinct effect of Rubcutaneous injection of the Rame dose.
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completely by the following day.
Subcutaneous injection of 100 mg./kg. of Irgapyrin pro-
duced gastric secretion comparable to that produced by the
foregoing two drugs. In this case, facial swelling was not
observed at all, even by precise measurement, and both redden-
ing and itching were entirely absent. The response of gastric
secretion to Irgapyrin was not increased or decreased by Neo-
Antergan, differing from the cases of sinomenine and histamine
(Table 3). However, repetition of its injection developed a fair
degree of refractoriness. Neither aminopyrine nor butazolidine
sodium caused gastric secretion or any other signs associated
with histamine release, when used individually in ·100 mg./kg.
dose.
In his clinical experience, Mannami (1955) observed that
the intramuscular injection of sinomenine failed to cause side
effects, such as facial edema and itching, which appear by its
subcutaneous injection. The present author also observed that
the intramuscular injection of sinomenine strangely did not
cause gastric secretion or any other signs usually seen after its
subcutaneous injection. However, both Compound 48/80 and
. Irgapyrin were effective by this route as by subcutaneous injec-
tion (Fig. 2).
Discussion
The results observed with sinomenine are pract.ically the
same as those reported for Compound 48/80 by Paton and
Schachter (1951), except for the earlier start of gastric secretion
induced by the former drug after the injection. Such similarity
of these snbstances may be understood by the fact that sinome-
nine shows pharmacological actions similar to Compound 48/80
as a specific histamine releaser (Mayeda, 1953; Yamasaki et al.
1955). Neo-Antergan markedly eliminated the signs and symp-
toms elicited by either of the injected or liberated histamine,
but did not suppress gastric secretion induced by histamine.
This indicates that the antihistamine is not capable of prevent-
ing the histamine release of sinomenine and suggests that the
suppression of histamine release by antihistamines may not be
as marked in vivo as in in vitro experiments (Tasaka, 1956).
6
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The increase of gastric secretion induced by sinomenine by
the concurrent use of Neo-Antergan may be explained by the
assumption made by Paton and Schachter that the edema of
gastric mucosa, which is known to reduce gastric secretion
(Ricketts, Kirsner and Palmer, 1949), occurs together with facial
swelling and this is eliminated by the antihistamine. In the
present series of experiments, Neo-Antergan seemed to give
slight but similar effect even in the case of histamine.
Irgapyrin was found to induce gastric secretion but it is
interesting that neither of its components, aminopyrine or
butazolidine sodium, possessed such action individually. Yama-
saki, Kamimura and Tasaka (1954), in their experiments on in
vitro histamine release using minced tissues of guinea pig lungs
and dog skin} found this action only in Irgapyrin among these
three drugs. More recently, Kume also proved the same relation
of these drugs in the effect of depleting skin histamine of the
unanesthetized dog by subcutaneous injections. It seems reason-
able, therefore, to assume that gastric secretion induced by
Irgapyrin is produced by histamine release. However, this
compound showed no other indications of histamine release, such
as facial swelling and itching. Such facts may also explain the
reason why Neo-Antergan had no influence on the gastric secre-
tion induced by Irgapyrin, differing from the case of sinome-
nine and Compound 48/80, because the edematous swelling of
gastric mucous membrane is not likely to be induced by Irga-
pyrin.
The foregoing facts also present the possibility that the
marked gastric secretion induced by Irgapyrin may occur chiefly
by some mechanisms other than histamine release. But, Kume
observed that the subcutaneous injection of five doses of 20
mg./kg. of Irgapyrin caused a reduction of skin histamine in
a dog, approximating that similarly caused by five 3 mg./kg.
of sinomenine. The amount of histamine released by 100 mg./kg.
of Irgapyrin may be sufficient to cause gastric secretion. Ano-
ther possibility is that Irgapyrin itself possesses an antihista-
minic action as well as a histamine-releasing action. If this is
the case, facial 8igns due to histamine release will not appear
and its gastric secretion will not be affected by Neo-Antergan.
This supposition is supported by the experimental result of
7
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W ilhelmi (1949) who demonstrated that Irgapyrin increased
the lethal dose of histamine in a guinea pig and alleviated the
spastic contraction of guinea-pig intestines and rabbit aural
vessels caused by his tamine.
It would be interesting to imagine that the excellent clinical
effect of Irgapyrin, compared to its components, is due to the
concurrent histamine-releasing action, because sinomenine, which
is a specific histamine liberator, also possesses an antirheumatic
effect (Ishiwari, 1921; Takaori, 1921). Investigations on this
point is now in progress in this laboratory. In any case, the
fact that these drugs clinically used so frequently induce gastric
secretion should be kept well in mind, especially in the case ofpeptic ulcer.
The reason of inability of the intramuscularly injected
sinomenine to induce gastric secretion is still obscure at the
present. Whether or not sinomenine reacts with muscular
tissue components, forming a complex that is not absorbed
easily, or losing its activity, is of interest for further studies.
Summary
1. Sinomenine and Irgapyrin, the two antirheumaticsknown to be capable of releasing histamine, caused a marked
gastric secretion in the unanesthetized dog.
2. The facial edema and itching associated with histamine
release by sinomenine was almost completely eliminated by Neo-
Antergan, but the gastric secretion was not suppressed, or
rather increased - an observation also reported by Paton andSchachter with Compound 48/80. This indicates that the hista-
mine release cannot be markedly prevented by antihistamine
agents in this animal.
3. The gastric secretion induced by Irgapyrin was not sup-
pressed by Neo-Antergan but Irgapyrin originally never caused
other symptoms associated with hist~mine release. This is pro-bably due to the antihistamine action inherent in this compounditself.
4. No such histamine-releasing activity, as determined by
gastric secretion, could be observed in aminopyrine or butazoli
dine sodium, the components of Irgapyrin.
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5. Sinomenine, differing from Irgapyrin and Compound
48/80, .was ineffective by intramuscular injection.
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